5 Amendments of Sirpa PIETIKÄINEN related to 2016/2057(INI)
Amendment 48 #
Motion for a resolution
Recital B a (new)
Recital B a (new)
Ba. whereas patients should have access to the healthcare and treatment options of their choice and preference, including to complementary and alternative therapies and medicines;
Amendment 79 #
Motion for a resolution
Recital D
Recital D
D. whereas in addition to high prices, other barriers to access to medicines include shortages of essential medicines, the poor connection between clinical needs and research, unjustified administrative procedures, unavailability of products, rigid patent rules and budget restrictions;
Amendment 290 #
Motion for a resolution
Paragraph 11 a (new)
Paragraph 11 a (new)
11a. Calls for the Commission and the Member States to agree on a common definition for added therapeutic value of medicines and aim at harmonised practices in its assessment;
Amendment 298 #
Motion for a resolution
Paragraph 12 a (new)
Paragraph 12 a (new)
12a. Welcomes the Commission’s work on creating more indicators to measure the outcomes of health care operations; Calls for the inclusion of added therapeutic value of a drug as an indicator when deciding on the reimbursement of medicines, as it happens that often drugs and personalised medicines with a higher price tag bring savings for the health care system in the longer term due to their more rapid efficacy;
Amendment 508 #
Motion for a resolution
Paragraph 25 a (new)
Paragraph 25 a (new)
25a. Calls on the Commission to establish a permanent and single mechanism assessing relative efficacy of new medicinal products at EU level based on harmonized data requirements, so as to enhance patient access to new treatments and avoid duplications in drug assessments;